Biomarin Pharmaceutical (BMRN) Cash from Operations Growth (1y) (2010 - 2026)
Biomarin Pharmaceutical (BMRN) Cash from Operations Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 158.60% |
| 10 | Biomarin Pharmaceutical | 11.67 Bn | 9.45 Bn | 571.21 Mn | 26.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.52% |
| Dec 31, 2025 | -46.32% |
| Sep 30, 2025 | 66.46% |
| Jun 30, 2025 | 56.00% |
| Mar 31, 2025 | 271.28% |
| Dec 31, 2024 | 575.42% |
| Sep 30, 2024 | 63.28% |
| Jun 30, 2024 | 69.51% |
| Mar 31, 2024 | 163.53% |
| Dec 31, 2023 | 305.00% |
| Sep 30, 2023 | -14.32% |
| Jun 30, 2023 | 24.61% |
| Mar 31, 2023 | -62.73% |
| Dec 31, 2022 | -39.30% |
| Sep 30, 2022 | 63.12% |
| Jun 30, 2022 | -32.08% |
| Mar 31, 2022 | -140.02% |
| Dec 31, 2021 | 183.53% |
| Sep 30, 2021 | 12.59% |
| Jun 30, 2021 | 198.46% |